Keunwha Pharm to produce amlodipine mesylate

Published: 2003-11-06 06:58:00

Updated: 2003-11-06 06:58:00

Keuhwha Pharm says it sign an agreement recently with Siegfried, a Switzerland-based pharmaceutical firm, for the inducement of the technology to manufacture and market amlodipine mesylate, antihypertensive agent until 2008 for the first time in Korea.

Siegfried is globally focused, independen...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK